Stockreport

Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress

Mural Oncology plc - Ordinary Shares  (MURA) 
PDF Key data readouts for the company’s late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian can [Read more]